Obacunone
Catalog No: CFN97233
Obacunone is a novel activator of Nrf2, which exhibits anti-cancer, anti-inflammatory, antivirulence, insecticidal, anti-proliferative and anti-aromatase activities. Obacunone stimulates muscle hypertrophy and prevents obesity and hyperglycemia, and that these beneficial effects are likely to be mediated through the activation of TGR5 and inhibition of PPARγ transcriptional activity. Obacunone significantly inhibits aromatase activity in an in vitro enzyme assay with an IC50 value of 28.04 μM, and it also inhibits the p38 MAPK signaling pathway.
Obovatol
Catalog No: CFN95054
Obovatol has antioxidant, neuroprotective, antiinflammatory, antithrombotic and antitumour effects, it is a potent NF-κB inhibitors for Alzheimer's disease treatment. Obovatol shows inhibitory effect on the Salmonella type III secretion system, it could be useful for the prevention and supplementary treatment of bacterial infections.
Obovatol inhibits receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL)-induced osteoclast differentiation in vitro and inflammatory bone loss in vivo, it may be a useful therapeutic agent for the treatment of pathological bone disorders characterized by excessive osteoclastic bone resorption.
Obtusifolin
Catalog No: CFN90394
Obtusifolin is a novel anti-breast-cancer bone metastasis agent, which has antioxidant, and antinociceptive properties.Obtusifolin has beneficial effects on the development of diabetic retinopathy via inhibition of accumulation of oxidatively modified DNA and nitrotyrosine in the retina, can help prevent vision loss in diabetic patients. Gluco-Obtusifolin and its aglycone may be useful for the treatment of cognitive impairment, and that its beneficial effects are mediated, in part, by the enhancement of cholinergic signaling.